Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:ATCCode |
nan
|
| gptkbp:CASNumber |
915385-81-8
|
| gptkbp:developedBy |
gptkb:United_Therapeutics
|
| gptkbp:hasMolecularFormula |
C20H19N5O4S
|
| gptkbp:hasSMILES |
CC(C)N(C1=NC=C(C2=CC=CC=C2)C(=N1)C3=CC=CC=C3)CCCCSCC(=O)O
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ralinepag
|
| gptkbp:isInClinicalTrialPhase |
Phase 3 (as of 2024)
|
| gptkbp:isInvestigationalDrugFor |
pulmonary arterial hypertension
|
| gptkbp:isNotYetApprovedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:isProstacyclinReceptorAgonist |
true
|
| gptkbp:IUPACName |
gptkb:2-((4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butyl)thio)acetic_acid
|
| gptkbp:mechanismOfAction |
selective prostacyclin (IP) receptor agonist
|
| gptkbp:molecularWeight |
425.46 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
gptkb:APD811
gptkb:UT-15C |
| gptkbp:bfsParent |
gptkb:Arena_Pharmaceuticals
|
| gptkbp:bfsLayer |
5
|